Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo
David Rosmarin,Thierry Passeron,Amit G Pandya,Pearl Grimes,John E Harris,Seemal R Desai,Mark Lebwohl,Mireille Ruer-Mulard,Julien Seneschal,Albert Wolkerstorfer,Deanna Kornacki,Kang Sun,Kathleen Butler,Khaled Ezzedine,TRuE-V Study Group,Ivan Botev,Mary Gantcheva,Sonia Marina,Marina Sankeva,Katya Zaharieva,Wayne Carey,Alim Devani,Melinda Gooderham,Charles Lynde,Kim Papp,Elena Poulos,Maryam Shayesteh Alam,Darryl Toth,Anne-Benedicte Duval-Modeste,Juliette Mazereeuw-Hautier,Roland Aschoff,Nina Magnolo,Michael Sebastian,Petra Staubach,Silvia Moretti,Samantha Berti,Olga Bobowska-Guglas,Dorotoa Bystrzanowska,Anna Elzakowska,Ryszard Galus,Tomasz Kolodziej,Lucyna Leszniewska,Elzbieta Polanowska-Palus,Joanna Renczynska-Matysko,Joanna Sienawska,Rafal Slugocki,Santa Vanaga-Besser,Jolanta Weglowska,Dorota Wielowieyska-Szybinska,Jacek Zdybski,Jose Lopez Estebaranz,Ane Jaka Moreno,Pedro Redondo,Idalia A Acosta,Mark S Amster,Andrew Blauvelt,Brent M Boyce,Robert Buka,Robert S Call,Kimberly S Cruz,Steven A Davis,James Q Del Rosso,Sunil S Dhawan,Janet C DuBois,Juan M Fernandez,Christina Feser,Seth B Forman,Anand K Ganesan,Amit Garg,Paul Gillum,Pearl E Grimes,Vlada Groysman,Barry S Horowitz,Richard H Huggins,Jeannette Jakus,Ernest Ast,Steven E Kempers,Theresa G Knoepp,Robert Koppel,Roopal Kundu,Vivian Laquer,Mark S Lee,Stuart Lessin,Amy J McMichael,Adnan Nasir,Anthony A Nuara,Elyse S Rafal,John K Randall,David Rayhan,Katherine Reed,Ali M Rkein,Mirwais Saifi,Raja Sivamani,Howard L Sofen,James A Solomon,Dow B Stough,James M Swinehart,Thomas Taylor,Jens Thiele,Ira H Jr Thorla,Gisela Torres-Bonilla,Kelly Yokum,Maria L Wei,Jeffrey M Weinberg,Jonathan Wolfe
DOI: https://doi.org/10.1056/NEJMoa2118828
2022-10-20
Abstract:Background: Vitiligo is a chronic autoimmune disease that causes skin depigmentation. A cream formulation of ruxolitinib (an inhibitor of Janus kinase 1 and 2) resulted in repigmentation in a phase 2 trial involving adults with vitiligo. Methods: We conducted two phase 3, double-blind, vehicle-controlled trials (Topical Ruxolitinib Evaluation in Vitiligo Study 1 [TRuE-V1] and 2 [TRuE-V2]) in North America and Europe that involved patients 12 years of age or older who had nonsegmental vitiligo with depigmentation covering 10% or less of total body-surface area. Patients were randomly assigned in a 2:1 ratio to apply 1.5% ruxolitinib cream or vehicle control twice daily for 24 weeks to all vitiligo areas on the face and body, after which all patients could apply 1.5% ruxolitinib cream through week 52. The primary end point was a decrease (improvement) of at least 75% from baseline in the facial Vitiligo Area Scoring Index (F-VASI; range, 0 to 3, with higher scores indicating a greater area of facial depigmentation), or F-VASI75 response, at week 24. There were five key secondary end points, including improved responses on the Vitiligo Noticeability Scale. Results: A total of 674 patients were enrolled, 330 in TRuE-V1 and 344 in TRuE-V2. In TRuE-V1, the percentage of patients with an F-VASI75 response at week 24 was 29.8% in the ruxolitinib-cream group and 7.4% in the vehicle group (relative risk, 4.0; 95% confidence interval [CI], 1.9 to 8.4; P<0.001). In TRuE-V2, the percentages were 30.9% and 11.4%, respectively (relative risk, 2.7; 95% CI, 1.5 to 4.9; P<0.001). The results for key secondary end points showed superiority of ruxolitinib cream over vehicle control. Among patients who applied ruxolitinib cream throughout 52 weeks, adverse events occurred in 54.8% in TRuE-V1 and 62.3% in TRuE-V2; the most common adverse events were application-site acne (6.3% and 6.6%, respectively), nasopharyngitis (5.4% and 6.1%), and application-site pruritus (5.4% and 5.3%). Conclusions: In two phase 3 trials, application of ruxolitinib cream resulted in greater repigmentation of vitiligo lesions than vehicle control through 52 weeks, but it was associated with acne and pruritus at the application site. Larger and longer trials are required to determine the effect and safety of ruxolitinib cream in patients with vitiligo. (Funded by Incyte; TRuE-V1 and TRuE-V2 ClinicalTrials.gov numbers, NCT04052425 and NCT04057573.).